Weekly Research Analysts’ Ratings Updates for TG Therapeutics (TGTX)

Several analysts have recently updated their ratings and price targets for TG Therapeutics (NASDAQ: TGTX):

• 10/8/2025 – TG Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – TG Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
• 10/6/2025 – TG Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
• 9/27/2025 – TG Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/17/2025 – TG Therapeutics had its price target raised by analysts at B. Riley from $53.00 to $55.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.64% of the stock is currently owned by company insiders.

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.